Cancer is a devastating disease. Immunotherapy can harness the body’s immune system to fight cancer.
Immune checkpoint inhibitors are revolutionary immunotherapy drugs; however, the response rates in some cancer types are still very low.
Addressing unmet needs, our cutting-edge science focuses on innovative antibodies to fine-tune the immune network in cancer.
Strong anti-tumor activity and minimal RBC binding
- High-affinity binding to CD47 on tumor cell
- Unique binding epitope on RBC hindered by membrane glycosylation
- Good safety profile
- No priming dose required
- No “sink effect”
- Anti-tumor activity in MDS, AML, and NHL
Unique intra-dimer binding through a C-terminus epitope of CD73 on tumor cell
- Complete CD73 inhibition without the “hook effect”
- Inhibition by a non-competitive manner, full target occupancy and sustained blockade compared to small-molecule inhibitor
- Potentially superior anti-tumor activity, especially in an adenosine-rich tumor micro-environment
Immune activation only upon tumor engagement
- Immune response targeted towards tumor cells, with minimal systemic toxicity
- Better efficacy than Claudin 18.2 or 4-1BB monotherapy, or combo
AI-guided novel biologics synthesis
Cell-penetrating antibody for intracellular target
Antibody synthesis in-vivo with mRNA
Local activation of masked antibody by tumor-specific protease at tumor site
Modular 4-1BB engaging bi-specific antibody platform